Brief: Karuna Therapeutics Submits New Drug Application To US FDA For Karxt For The Treatment Of Schizophrenia
28/09/2023 11:46
Sept 28 (Reuters) - Karuna Therapeutics Inc KRTX.O :
* KARUNA THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S.
FOOD
AND DRUG ADMINISTRATION FOR KARXT FOR THE TREATMENT OF
SCHIZOPHRENIA
* KARUNA THERAPEUTICS INC - KARXT WAS FOUND TO BE GENERALLY
WELL-TOLERATED
* KARUNA THERAPEUTICS INC - KARXT WAS NOT ASSOCIATED WITH
COMMON
SIDE EFFECTS OF CURRENTLY AVAILABLE ANTIPSYCHOTICS
Source text for Eikon: ID:nBwbQKT04a
Further company coverage: KRTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Karuna Therapeutics
See all newsMoody's says pharma outlook turns 'positive' on GLP-1 drug push
Brief: Karuna Therapeutics Says Complaint Was Filed By Karuna Stockholder Seeking To Enjoin Proposed Merger With Bristol-Myers Squibb
Karuna Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Karuna Therapeutics Inc expected to post a loss of $2.65 a share - Earnings Preview
Bristol Myers posts better-than-expected 4th-quarter results (updated)